Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. MSFT
6. NAVN
7. DFTX
8. CNC
9. KFY
10. SPY

Go back to Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Acceleron Pharma (XLRN) PT Raised to $62 at UBS

July 10, 2018 8:01 AM EDT

UBS raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.

... More

Acceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results

July 10, 2018 7:34 AM EDT

H.C. Wainwright raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $74.00 (from $69.00) while maintaining a Buy rating following the company's announcement, along with Celgene (NASDAQ: CELG), of positive results from the Phase 3 BELIEVE study of luspatercept in... More